Key result
Cardiac contractility modulation therapy improved mean LVEF from 27% to 35%, NYHA class from 3.9 to 2.4, and 6-minute walk distance from 159 m to 212 m over 6 months in 10 patients with HFrEF.
Why the study?
Does cardiac contractility modulation therapy improve symptoms and outcomes in patients with moderately severe heart failure?
Design
Editorial
Authors
Loading...
May benefit narrow-QRS or AF patients ineligible for CRT; hypothesis-generating and requires randomized confirmation.
Does cardiac contractility modulation therapy improve symptoms and outcomes in patients with moderately severe heart failure?
This editorial highlights the expanding role of cardiac contractility modulation therapy for symptomatic heart failure patients, particularly those with narrow QRS or atrial fibrillation who are ineligible for CRT.
Samii et al. (2022) conducted an editorial in chronic heart failure with reduced ejection fraction (HFrEF) (n=10). Cardiac contractility modulation (CCM) therapy was evaluated. Cardiac contractility modulation therapy improved mean LVEF from 27% to 35%, NYHA class from 3.9 to 2.4, and 6-minute walk distance from 159 m to 212 m over 6 months in 10 patients with HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: